Takahiro Ikura1, Omi Katsuse2, Yuhei Chiba1, Yukitoshi Takahashi3, Hiroshige Fujishiro4, Ayuko Kamada1, Tomoyuki Saito1, Yoshio Hirayasu1. 1. Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan. 2. Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama City, Kanagawa 236-0004, Japan. Electronic address: oxm08@yahoo.co.jp. 3. Shizuoka Institute of Epilepsy and Neurological Disorders, 886 Urushiyama, Aoi-ku, Shizuoka City, Shizuoka 420-8688, Japan. 4. Department sleep of medicine, Nagoya University Graduate School of Medicine, 65 Turumaichou, Shouwa-ku, Nagoya City, Aiti 466-8550, Japan.
Abstract
BACKGROUND: Patients with anti-thyroid antibodies (ATAs) are reported to exhibit atypical psychiatric symptoms. We have been reported that psychiatric patients with ATAs (PPATs) have anti-N-methyl-Daspartate (NMDA) type glutamate receptor (NMDA-R) antibodies by western blot analysis. NMDA-R forms a tetramer with the subunit glutamate receptors (GluR) GluRζ1 (NR1) and GluRε2 (NR2B). However, the possible etiological role of anti-NR1 and anti-NR2B antibodies in PPATs remains unclear. METHODS: First, we evaluated titers of anti-NR1 and anti-NR2B antibodies in PPATs by enzyme-linked immunosorbent assay (ELISA). Next, we investigated the relationships among titers of anti-NR1 and anti-NR2B antibodies. Finally, we investigated the relationship between anti-NMDAR antibodies and the psychiatric symptoms in the PPATs. RESULTS: There was a strong correlation between anti-NR1 antibodies and anti-NR2B antibodies in the CSF, and some correlation between these antibodies in the serum. High titers of anti-NR2B antibodies in the serum of PPATs contributed to development of hallucinations and high titers of anti-NR1 antibodies in the serum contributed to development of anxiety by logistic regression. CONCLUSION: High titers of anti-NR2B antibodies in the serum is a risk factor for hallucinations and high titers of anti-NR1 antibodies in the serum is a risk factor for anxiety in PPATs.
BACKGROUND:Patients with anti-thyroid antibodies (ATAs) are reported to exhibit atypical psychiatric symptoms. We have been reported that psychiatricpatients with ATAs (PPATs) have anti-N-methyl-Daspartate (NMDA) type glutamate receptor (NMDA-R) antibodies by western blot analysis. NMDA-R forms a tetramer with the subunit glutamate receptors (GluR) GluRζ1 (NR1) and GluRε2 (NR2B). However, the possible etiological role of anti-NR1 and anti-NR2B antibodies in PPATs remains unclear. METHODS: First, we evaluated titers of anti-NR1 and anti-NR2B antibodies in PPATs by enzyme-linked immunosorbent assay (ELISA). Next, we investigated the relationships among titers of anti-NR1 and anti-NR2B antibodies. Finally, we investigated the relationship between anti-NMDAR antibodies and the psychiatric symptoms in the PPATs. RESULTS: There was a strong correlation between anti-NR1 antibodies and anti-NR2B antibodies in the CSF, and some correlation between these antibodies in the serum. High titers of anti-NR2B antibodies in the serum of PPATs contributed to development of hallucinations and high titers of anti-NR1 antibodies in the serum contributed to development of anxiety by logistic regression. CONCLUSION: High titers of anti-NR2B antibodies in the serum is a risk factor for hallucinations and high titers of anti-NR1 antibodies in the serum is a risk factor for anxiety in PPATs.